Close

Rigel Pharma (RIGL) Oral Spleen Tyrosine Kinase (SYK) Inhibitor Met Primary Endpoint in Phase 3 Study

Go back to Rigel Pharma (RIGL) Oral Spleen Tyrosine Kinase (SYK) Inhibitor Met Primary Endpoint in Phase 3 Study